The earlier the better!

Diagnosing Bechterew’s disease

Your molecular genetic test systems for the fast and reliable detection of the HLA-B27 allele:

GenoQuick® HLA-B27
FluoroType® HLA-B27

Your benefits of using a HLA-B27 detection from Hain Lifescience

• **Definite result:** With both test systems all relevant subtypes of HLA-B27 are detected.

• **Early diagnosis:** The high diagnostic value obtained through genotyping provides an important therapeutic head start. This allows treatment measures to be taken early and helps to control the course of the disease.

• **No living cells are required:** As opposed to flow cytometry, patient samples can be kept for extended periods of time. This means that even small serial runs can be processed efficiently.

• **Cost-efficient:** No expensive instruments are required, allowing even small laboratories to carry out competitive testing.

• **User-friendly:** Our test systems require only minimal pipetting effort, thus saving time and guarantying efficient routine diagnostic procedures.

• **CE 0483 - IVD certified:** No need for elaborate validation studies!
Facts

Approximately 90% of all the patients suffering from Bechterew’s disease are HLA-B27 positive. So the detection of this allele has high informative value for the probability of developing Bechterew’s disease.

Bechterew’s disease is a chronic rheumatic disease that mainly affects the spine. The first symptoms of this disease include difficulties in movement affecting the lumbar spine region. As the disease progresses, the symptoms become more pronounced, eventually leading to bony stiffening of the spine.

The first symptoms are frequently non-specific and generally not associated with the disease. As a result of this, it often takes 5–10 years from initial symptoms to definitive diagnosis. However, early diagnosis is essential because the evolution of the disease can be controlled more effectively during early phases.

Since 8% of the healthy population tests positive for HLA-B27, the presence of this allele should be regarded as a risk factor and not be taken as a confirmation of the existence of the disease. Along with the clarification of additional parameters, for example, the presence of a positive family history, the test result makes a definite diagnosis possible.

The choice is yours: Two different test systems for the reliable HLA-B27 detection!

For further information please contact Hain Lifescience or your local distributor!

Hain Lifescience GmbH
Hardwiesenstrasse 1 | 72147 Nehren | Germany
Tel.: +49 (0) 74 73- 94 51- 0 | Fax: +49 (0) 74 73- 94 51- 31
E-Mail: info@hain-lifescience.de | www.hain-lifescience.de